Julie Margenthaler

Medicine & Life Sciences

1. Adjuvant Chemotherapy 8%
2. African Americans 12%
3. Anastrozole 7%
4. Axilla 5%
5. Biopsy 7%
6. Brachytherapy 9%
7. Breast 45%
8. Breast Diseases 6%
9. Breast Neoplasms 100%
10. Cancer Survivors 6%
11. Carcinoma, Intraductal, Noninfiltrating 22%
12. Drug Therapy 11%
13. Epidemiology 6%
14. Estrogen Receptors 6%
15. Guidelines 6%
16. Heart 6%
17. Incidence 5%
18. Isoantigens 6%
19. Lymph Node Excision 5%
20. Lymph Nodes 12%
21. Mammaplasty 18%
22. Mastectomy 42%
23. Mortality 6%
24. Neoadjuvant Therapy 9%
25. Neoplasm Metastasis 7%
26. Neoplasms 24%
27. Nipples 7%
28. Oncologists 5%
29. Prophylactic Mastectomy 6%
30. Propionibacterium acnes 6%
31. Radiation 6%
32. Radiotherapy 10%
33. Randomized Controlled Trials 7%
34. Recurrence 16%
35. Segmental Mastectomy 34%
36. Sentinel Lymph Node 13%
37. Sentinel Lymph Node Biopsy 12%
38. Shared Decision Making 5%
39. Skin 8%
40. Surgeons 11%
41. Surgical Wound Infection 9%
42. Survival 11%
43. T-Lymphocytes 6%
44. Therapeutics 11%
45. Tissue Expansion Devices 8%
46. Transgenic Mice 6%
47. Transplantation Tolerance 6%
48. Transplants 5%
49. Triple Negative Breast Neoplasms 17%
50. Ultrasonography 5%